Cardiovascular outcome trials in type 2 diabetes: A nurse practitioner perspective

被引：4

作者：

Kruger, Davida F. ^{[1
]}

机构：

[1] Henry Ford Hlth Syst, Div Endocrinol Diabet Bone & Mineral Dis, 3031 West Grand Blvd Suite 800, Detroit, MI 48202 USA

来源：

JOURNAL OF THE AMERICAN ASSOCIATION OF NURSE PRACTITIONERS | 2018年 / 30卷

关键词：

Cardiovascular disease; glucagon-like peptide-1; glucose-lowering therapy; semaglutide; type; 2; diabetes; PEPTIDE-1 RECEPTOR AGONISTS; INTENSIVE GLUCOSE CONTROL; HEART-FAILURE; FOLLOW-UP; MELLITUS; MORTALITY; METAANALYSIS; DISEASE; RISK; LIRAGLUTIDE;

D O I：

10.1097/JXX.0000000000000126

中图分类号：

R19 [保健组织与事业（卫生事业管理）];

学科分类号：

摘要：

To provide an overview of cardiovascular outcome trials (CVOT) with once-weekly glucagon-like peptide-1 receptor agonists (GLP-1RAs), and other recent CVOTs, and to discuss the implications for the management of patients with type 2 diabetes (T2D). Details of completed and ongoing CVOTs of glucose-lowering drugs from primary articles and ClinicalTrials.gov were collated and critically reviewed for information relating to patient populations and primary outcomes. Cardiovascular outcome trials have demonstrated the cardiovascular (CV) safety of a number of new glucose-lowering drugs. Recent trials suggest that some glucose-lowering drugs-including the once-weekly GLP-1RA semaglutide (post hoc analysis) and once-daily liraglutide-may reduce the risk of CV events in patients with T2D and high CV risk. Given their prime role in managing treatment choices for patients with T2D, nurse practitioners should strongly consider prescribing therapies, such as GLP-1RAs, that offer improved glycemic control, weight loss, a low risk of hypoglycemia, and beneficial CV outcomes.

引用

页码：S43 / S52

页数：10

共 56 条

[1] Mode of administration of dulaglutide: implications for treatment adherence [J].

Amblee, Ambika .

PATIENT PREFERENCE AND ADHERENCE, 2016, 10 :975-982

[2]

[Anonymous], 2018, DIABETES CARE, V41, pS1, DOI [10.2337/dc18-SINT01, 10.2337/dc18-Sint01]

[3]

[Anonymous], CIRCULATION

[4]

[Anonymous], 2016, BI 10773 EMP CARD OU

[5] Rationale, design, and baseline characteristics in Evaluation of LIXisenatide in Acute Coronary Syndrome, a long-term cardiovascular end point trial of lixisenatide versus placebo [J].

Bentley-Lewis, Rhonda ;

Aguilar, David ;

Riddle, Matthew C. ;

Claggett, Brian ;

Diaz, Rafael ;

Dickstein, Kenneth ;

Gerstein, Hertzel C. ;

Johnston, Peter ;

Kober, Lars V. ;

Lawson, Francesca ;

Lewis, Eldrin F. ;

Maggioni, Aldo P. ;

McMurray, John J. V. ;

Ping, Lin ;

Probstfield, Jeffrey L. ;

Solomon, Scott D. ;

Tardif, Jean-Claude ;

Wu, Yujun ;

Pfeffer, Marc A. .

AMERICAN HEART JOURNAL, 2015, 169 (05) :631-U75

[6]

ClinicalTrials. gov, 2017, STUD ASS CARD OUTC F

[7]

ClinicalTrials. gov, 2014, DOES SAX RED RISK CA

[8]

ClinicalTrials. gov, 2017, CARD REN MICR OUTC S

[9]

ClinicalTrials. gov, 2017, EFF ALB ADD STAND BL

[10]

ClinicalTrials. gov, 2016, RES CARD EV WEEKL IN

← 1 2 3 4 5 6 →